This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

Home20 Serotypes20 SerotypesSerotype coverageCase CoverageDisease BurdenEfficacyEfficacyInvasive Pneumococcal DiseaseOtitis MediaClinical Trial Results

Clinical Trial
Results

Study DesignImmunogenicitySafetyDosing & RecommendationsOrdering & ResourcesOrdering &
ResourcesOrder Prevnar 20®Commercial health plansEventsMaterialsVideosResourcesRequest a Representative
Prescribing InformationPatient InformationIndications Patient Site
Order directly through the Pfizer online ordering system, Pfizer PrimeOrder directly through the Pfizer online ordering system, Pfizer PrimeOnline ordering allows you to submit an order for Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) that will ship in 2-3 business daysOnline ordering allows you to submit an order for Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) that will ship in 2-3 business days
Cost and coverage calculator
 New Customers

To establish a new online ordering account, please contact your Pfizer Representative or call [1-800-666-7248].

 Call [1-800-666-7248] Loading Existing Customers

Already have an online ordering account? Manage your account or place a new order.

 Manage your account Loading
Access and enrollment based on MMIT formulary information as of [EFFECTIVE_DATE] and represents the local area, based on the first three digits of the ZIP code.
CPT®* Code NDC #
906771




 		 NDC 0005-2000-10 (Prevnar 20® 10-pack pre-filled syringes)1 

NDC 0005-2000-02 (Prevnar 20® individual pre-filled syringe)1

*CPT is a registered trademark of the American Medical Association (AMA).

Storage, handling, and administration

Storage, handling, and administration

Important Packaging Information
  • Upon FDA approval of Prevnar 20® for pediatric use, Pfizer will be removing the statement “FOR USE IN INDIVIDUALS 18 YEARS OF AGE AND OLDER” from newly manufactured boxes
  • In the interim, product in its original packaging can be used in appropriate infants and children
  • Store pre-filled syringes in the refrigerator (2°C to 8°C). Do not freeze1
  • To minimize resuspension time, syringes should be stored horizontally, as directed on packaging1
  • Once removed from the refrigerator, Prevnar 20® should be used immediately1†
ReferencesStability data indicate that the vaccine is stable for 96 hours when stored at temperatures from 8°C to 25°C, or 72 hours when stored at temperatures from 0°C to 2°C. At the end of these time periods, Prevnar 20® should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.1Prevnar 20® is prepared and administered the same as Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])1,2
Preparation1
Do not mix Prevnar 20® with other vaccines/products in the same syringe.

Step 1: Resuspend drug product

  • Hold the pre-filled syringe horizontally between the thumb and the forefinger and shake vigorously until the vaccine is a homogeneous white suspension
​​​​​​​
  • Do not use the vaccine if it cannot be resuspended

Step 2: Visual inspection

  • Visually inspect the vaccine for large particulate matter and discoloration prior to administration
 
  • Do not use if large particulate matter or discoloration is found. If the vaccine is not a homogeneous suspension, repeat Steps 1 and 2

Step 3: Remove syringe cap

  • Remove the syringe cap by slowly turning the cap counterclockwise while holding the Luer lock adapter
  • Avoid pressing the syringe plunger rod while removing the syringe cap

Step 4: Attach a sterile needle

Hold the Luer lock adapter and attach a needle appropriate for intramuscular administration to the pre-filled syringe by turning clockwise
Administration1
  • For intramuscular injection only
  • Each 0.5-mL dose is to be injected intramuscularly using a sterile needle attached to the supplied pre-filled syringe
    • The preferred sites for injection are the anterolateral aspect of the thigh in infants and the deltoid muscle of the upper arm in children and adults
References:Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information, Wyeth Pharmaceuticals LLC, 2023.Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information, Wyeth Pharmaceuticals LLC, 2019.
Manufactured by Wyeth Pharmaceuticals LLC.
Marketed by Pfizer Inc.
PP-PNR-USA-2906 © 2025 Pfizer Inc.
All rights reserved. April 2025
Ordering & Resources Learn about the importance of completing all 4 doses on time Go Now
Built on the legacy of Prevnar® (PCV7) and Prevnar 13®
 See How

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2906
You are now leaving PfizerPro
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
INDICATIONS 
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Both Prevnar 20® and Prevnar 13® are vaccines indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age
  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in individuals 6 weeks through 17 years of age
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine.
Important Safety Information
  • Do not administer Prevnar 20® or Prevnar 13® to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or Prevnar 13® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups, and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response to Prevnar 13®
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and risks
  • For Prevnar 20®, in individuals 2, 4, 6, and 12 through 15 months of age vaccinated with a 4-dose schedule, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, decreased appetite, injection site redness, injection site swelling, and fever
  • For Prevnar 20®, in individuals 15 months through 17 years of age vaccinated with a single dose, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, fatigue and muscle pain, decreased appetite, injection site swelling, injection site redness, headache, and fever
  • For Prevnar 13®, in individuals 6 weeks through 17 years of age, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
  • For Prevnar 13®, in individuals 6 weeks through 17 years of age, the most common side effects were irritability, decreased appetite, decreased or increased sleep, fever, and injection site tenderness, redness, or swelling
  • In individuals 6 years through 17 years of age, Prevnar 13® is administered as a single dose
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® full Prescribing Information.

Please click for Prevnar 13® full Prescribing Information.Indications
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Both Prevnar 20® and Prevnar 13® are vaccines indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age
  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in individuals 6 weeks through 17 years of age
Prevnar 13® Limitations of Use: Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine.